NUWE - Nuwellis Inc

NUWE - Nuwellis Inc

https://www.nuwellis.com

Recent News

Powered by Alpha Vantage

Nuwellis Introduces New 24-Hour Aquadex™ Circuit to Support Hospital-Based Outpatient and Short-Term Fluid Management

GlobeNewswire • 1 week, 4 days ago • score: 0.50

Nuwellis, Inc., a fluid management company, announced plans to introduce a new 24-hour circuit for Aquadex therapy in the United States this fall.

Nuwellis Introduces New 24-Hour Aquadex™ Circuit to Support Hospital-Based Outpatient and Short-Term Fluid Management - Nuwellis ( NASDAQ:NUWE )

Benzinga • 1 week, 4 days ago • score: 0.48

MINNEAPOLIS, Sept. 04, 2025 ( GLOBE NEWSWIRE ) -- Nuwellis, Inc., a fluid management company, announced plans to introduce a new 24-hour circuit for Aquadex therapy in the United States this fall.

Nuwellis Receives FDA 510 ( k ) Clearance for New Dual Lumen Extended Length Catheter

GlobeNewswire • 3 weeks, 4 days ago • score: 0.56

MINNEAPOLIS, Aug. 21, 2025 ( GLOBE NEWSWIRE ) -- Nuwellis, Inc. ( Nasdaq: NUWE ) , a medical technology company focused on fluid management, today announced it has received U.S. Food and Drug Administration ( FDA ) 510 ( k ) clearance for a new size of its Dual Lumen Extended Length Catheter ( ...

Nuwellis Receives FDA 510 ( k ) Clearance for New Dual Lumen Extended Length Catheter - Nuwellis ( NASDAQ:NUWE )

Benzinga • 3 weeks, 4 days ago • score: 0.53

MINNEAPOLIS, Aug. 21, 2025 ( GLOBE NEWSWIRE ) -- Nuwellis, Inc. NUWE, a medical technology company focused on fluid management, today announced it has received U.S. Food and Drug Administration ( FDA ) 510 ( k ) clearance for a new size of its Dual Lumen Extended Length Catheter ( dELC ) .

Nuwellis Signs Letter of Intent to Explore Acquisition of Rendiatech Ltd., A Real-Time Fluid Monitoring Company

GlobeNewswire • 3 weeks, 6 days ago • score: 0.38

Proposed acquisition supports strategy to drive technology expansion of fluid management offering to include continuous renal health monitoring technologies supporting the full patient journey, from early risk assessment to targeted fluid removal ...

Nuwellis Signs Letter of Intent to Explore Acquisition of Rendiatech Ltd., A Real-Time Fluid Monitoring Company - Nuwellis ( NASDAQ:NUWE )

Benzinga • 3 weeks, 6 days ago • score: 0.37

Proposed acquisition supports strategy to drive technology expansion of fluid management offering to include continuous renal health monitoring technologies supporting the full patient journey, from early risk assessment to targeted fluid removal MINNEAPOLIS, Aug. 19, 2025 ( GLOBE NEWSWIRE ) -- ...

Nuwellis, Inc. to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

GlobeNewswire • 1 month ago • score: 0.05

Live video webcast on Thursday, August 21st at 2:40 PM ET Live video webcast on Thursday, August 21st at 2:40 PM ET ...

Nuwellis, Inc. Reports Second Quarter 2025 Financial Results and Business Highlights

GlobeNewswire • 1 month ago • score: 0.29

MINNEAPOLIS, Aug. 14, 2025 ( GLOBE NEWSWIRE ) -- Nuwellis, Inc. ( Nasdaq: NUWE ) , a commercial-stage medical technology company dedicated to transforming care for fluid overload patients, today announced financial results for the second quarter ended June 30, 2025, and provided a business ...

Nuwellis to Exit International Operations to Accelerate U.S. Revenue Growth and Strategic Focus

GlobeNewswire • 1 month, 1 week ago • score: 0.52

MINNEAPOLIS, Aug. 07, 2025 ( GLOBE NEWSWIRE ) -- Nuwellis, Inc. ( Nasdaq: NUWE ) , a medical technology company delivering fluid management solutions for critically ill patients, today announced its decision to exit international operations in order to focus exclusively on the U.S. market-where ...

Nuwellis to Exit International Operations to Accelerate U.S. Revenue Growth and Strategic Focus - Nuwellis ( NASDAQ:NUWE )

Benzinga • 1 month, 1 week ago • score: 0.50

MINNEAPOLIS, Aug. 07, 2025 ( GLOBE NEWSWIRE ) -- Nuwellis, Inc. NUWE, a medical technology company delivering fluid management solutions for critically ill patients, today announced its decision to exit international operations in order to focus exclusively on the U.S. market-where the company is ...

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Nuwellis, Inc., a medical device company, focuses on the development, manufacture and marketing of medical devices used in ultrafiltration therapy. The company is headquartered in Eden Prairie, Minnesota.

52W High

$175.98

52W Low

$4.67

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

0.18

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-0.34

EV/Revenue (<3 favorable)

0.05

P/S (TTM) (<3 favorable)

0.53

P/B (<3 favorable)

2.58

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

2.92%

Institutions (25–75% balanced)

1.49%

Shares Outstanding

902,660

Float

876,130

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

8,318,000

Gross Profit (TTM)

5,186,000

EPS (TTM)

-313.92

Profit Margin (>10% good)

-1.76%

Operating Margin (TTM) (higher better)

-1.69%

ROE (TTM) (>15% strong)

-4.41%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

-0.21

Momentum

Value

N/A

Previous

N/A

Trend

—

Signal Cross

No cross

As of

—